Bioequivalence and Bioavailability Forum 14:01 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA Recommendation on Matrix Effect Determination in CC Assay [Bioanalytics]

posted by Obinoscopy - Nigeria, 2018-10-01 14:38  - Posting: # 19351
Views: 292

Hi Guys,

I am going through the FDA BMV guideline and I noticed they didn't give any specific guidance on how to validate that a Chromatographic Assay method is free from Matrix Effect.

All I saw was this:

"Sponsor should ensure that there are no matrix effect throughout the application of the method"

No detail on how this could be achieved was provided.

For Ligand Binding Assays, they did give some hint on how to evaluate Matrix Effect but no Acceptance Criteria was provided.

Why is this so? Could it be that there are different school of thoughts on how to evaluate matrix effect and the FDA is trying not to take sides?

I personally feel they should have provided a method of evaluating matrix effect. Either they provide that which is in tandem with the EMA or they provide an alternative.

Or what do you think?

Regards,

Scopy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,782 posts in 4,002 threads, 1,257 registered users;
online 19 (1 registered, 18 guests [including 15 identified bots]).

Power Calculation – A guess masquerading
as mathematics.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed